×
About 2,952 results

ALLMedicine™ Chordoma Center

Research & Reviews  1,453 results

Vision loss following high-dose proton-based radiotherapy for skull-base chordoma and c...
https://doi.org/10.1016/j.radonc.2021.02.012
Radiotherapy and Oncology : Journal of the European Socie... De Leo AN, Holtzman AL et. al.

Feb 21st, 2021 - Dose escalation for skull-based chordoma and chondrosarcoma can put critical adjacent structures at risk, specifically the anterior optic pathway. We report the incidence of vision loss following high-dose conformal proton-based radiotherapy. We r...

Cytomorphologic Spectrum of SMARCB1-Deficient Soft Tissue Neoplasms.
https://doi.org/10.1093/ajcp/aqaa223
American Journal of Clinical Pathology; Schaefer IM, Al-Ibraheemi A et. al.

Feb 20th, 2021 - The SWI/SNF complex core subunit SMARCB1 is inactivated in a variety of neoplasms that share characteristic "rhabdoid" cytomorphology. The aim of this study was to evaluate SMARCB1-deficient soft tissue neoplasms on cytology to identify diagnostic...

Randomized, Double-Blind, Placebo-Controlled Phase II Study of Yeast-Brachyury Vaccine ...
https://doi.org/10.1002/onco.13720
The Oncologist; DeMaria PJ, Bilusic M et. al.

Feb 17th, 2021 - Brachyury is a transcription factor overexpressed in chordoma and is associated with chemotherapy resistance and epithelial-to-mesenchymal transition. GI-6301 is a recombinant, heat-killed Saccharomyces cerevisiae yeast-based vaccine targeting bra...

Chordoma of the sacrum and mobile spine: a narrative review.
https://doi.org/10.1016/j.spinee.2020.10.009
The Spine Journal : Official Journal of the North America... Pennington Z, Ehresman J et. al.

Feb 16th, 2021 - Chordoma is a notochord-derived primary tumor of the skull base and vertebral column known to affect 0.08 to 0.5 per 100,000 persons worldwide. Patients commonly present with mechanical, midline pain with or without radicular features secondary to...

Free tissue transfer for central skull base defect reconstruction: Case series and surg...
https://doi.org/10.1016/j.oraloncology.2021.105220
Oral Oncology; Sagheer SH, Swendseid B et. al.

Feb 16th, 2021 - Local reconstruction of central skull base defects may be inadequate for large defects or reoperative cases; free tissue transfer may be necessary. Inset of the flap and management of the pedicle can be challenging. We report our experience and ap...

see more →

Guidelines  2 results

NCCN Guidelines Insights: Bone Cancer, Version 2.2017
http://www.jnccn.org/content/15/2/155.full
Biermann, J.,et al

Jan 31st, 2017 - The NCCN Guidelines for Bone Cancer provide interdisciplinary recommendations for treating chordoma, chondrosarcoma, giant cell tumor of bone, Ewing sarcoma, and osteosarcoma. These NCCN Guidelines Insights summarize the NCCN Bone Cancer Panel's g.

Bone cancer.
https://doi.org/10.6004/jnccn.2013.0088
Journal of the National Comprehensive Cancer Network : JN... Biermann JS, Adkins DR et. al.

Jun 7th, 2013 - Primary bone cancers are extremely rare neoplasms, accounting for fewer than 0.2% of all cancers. The evaluation and treatment of patients with bone cancers requires a multidisciplinary team of physicians, including musculoskeletal, medical, and r...

see more →

Clinicaltrials.gov  1,477 results

Vision loss following high-dose proton-based radiotherapy for skull-base chordoma and c...
https://doi.org/10.1016/j.radonc.2021.02.012
Radiotherapy and Oncology : Journal of the European Socie... De Leo AN, Holtzman AL et. al.

Feb 21st, 2021 - Dose escalation for skull-based chordoma and chondrosarcoma can put critical adjacent structures at risk, specifically the anterior optic pathway. We report the incidence of vision loss following high-dose conformal proton-based radiotherapy. We r...

Cytomorphologic Spectrum of SMARCB1-Deficient Soft Tissue Neoplasms.
https://doi.org/10.1093/ajcp/aqaa223
American Journal of Clinical Pathology; Schaefer IM, Al-Ibraheemi A et. al.

Feb 20th, 2021 - The SWI/SNF complex core subunit SMARCB1 is inactivated in a variety of neoplasms that share characteristic "rhabdoid" cytomorphology. The aim of this study was to evaluate SMARCB1-deficient soft tissue neoplasms on cytology to identify diagnostic...

Randomized, Double-Blind, Placebo-Controlled Phase II Study of Yeast-Brachyury Vaccine ...
https://doi.org/10.1002/onco.13720
The Oncologist; DeMaria PJ, Bilusic M et. al.

Feb 17th, 2021 - Brachyury is a transcription factor overexpressed in chordoma and is associated with chemotherapy resistance and epithelial-to-mesenchymal transition. GI-6301 is a recombinant, heat-killed Saccharomyces cerevisiae yeast-based vaccine targeting bra...

Chordoma of the sacrum and mobile spine: a narrative review.
https://doi.org/10.1016/j.spinee.2020.10.009
The Spine Journal : Official Journal of the North America... Pennington Z, Ehresman J et. al.

Feb 16th, 2021 - Chordoma is a notochord-derived primary tumor of the skull base and vertebral column known to affect 0.08 to 0.5 per 100,000 persons worldwide. Patients commonly present with mechanical, midline pain with or without radicular features secondary to...

Free tissue transfer for central skull base defect reconstruction: Case series and surg...
https://doi.org/10.1016/j.oraloncology.2021.105220
Oral Oncology; Sagheer SH, Swendseid B et. al.

Feb 16th, 2021 - Local reconstruction of central skull base defects may be inadequate for large defects or reoperative cases; free tissue transfer may be necessary. Inset of the flap and management of the pedicle can be challenging. We report our experience and ap...

see more →

News  11 results

FDA places tazemetostat trials on partial hold
https://www.mdedge.com/hematology-oncology/article/184994/lymphoma-plasma-cell-disorders/fda-places-tazemetostat-trials-partial-hold
HT Staff

Apr 25th, 2018 - The US Food and Drug Administration (FDA) has placed a partial hold on clinical trials of tazemetostat, an EZH2 inhibitor being developed to treat solid tumors and lymphomas. The hold has halted enrollment in US-based trials of tazemetostat, but s.

Treating Bone and Soft Tissue Sarcomas
https://www.onclive.com/publications/oncology-live/2015/october-2015/treating-bone-and-soft-tissue-sarcomas

Oct 15th, 2015 - Jonathan C. Trent, MD, PhD Breelyn A. Wilky, MD Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine Miami, FL Determining the best course of treatment for sarcomas of the bone and soft tissues is a complex process. ...

New Guidelines for Chordoma
https://www.mdedge.com/neurology/article/98601/new-guidelines-chordoma

Apr 8th, 2015 - Patients with chordoma, caregivers, and health care professionals have a new resource to aid in their fight against chordoma, with the publication of the first detailed, multidisciplinary treatment guidelines in the journal The Lancet Oncology. Th.

New guidelines for chordoma
https://www.mdedge.com/neurology/article/98606/rare-diseases/new-guidelines-chordoma

Apr 8th, 2015 - Chordoma patients, caregivers, and health care professionals have a new resource to aid in their fight against chordoma, with the publication of the first detailed, multidisciplinary treatment guidelines in the journal The Lancet Oncology. These r.

see more →

Patient Education  9 results see all →